Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics

Cancer

Volumn 123, Issue 19, 2017, Pages 3843-3854

  Ocean, Allyson J ^a   Starodub, Alexander N ^b,i   Bardia, Aditya ^c   Vahdat, Linda T ^a   Isakoff, Steven J ^c   Guarino, Michael ^d   Messersmith, Wells A ^e   Picozzi, Vincent J ^f   Mayer, Ingrid A ^g   Wegener, William A ^h   Maliakal, Pius ^h   Govindan, Serengulam V ^h   Sharkey, Robert M ^h   Goldenberg, David M ^h  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b INDIANA UNIVERSITY HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HELEN F GRAHAM CANCER CENTER   (United States)

^e UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^f Virginia Mason Health System   (United States)

^g VANDERBILT INGRAM CANCER CENTER   (United States)

^h IMMUNOMEDICS INC   (United States)

ⁱ Parkview Heart Institute   (United States)

Author keywords

antibody drug conjugate; clinical trial; epithelial cancers; IMMU 132 (sacituzumab govitecan); SN 38; trophoblastic cell surface antigen (Trop 2)

Indexed keywords

FIRTECAN; GLUCURONOSYLTRANSFERASE 1A1; IMMU 32; SACITUZUMAB GOVITECAN; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CELL ADHESION MOLECULE; GLUCURONOSYLTRANSFERASE; IMMUNOGLOBULIN G; IRINOTECAN; MONOCLONAL ANTIBODY; TACSTD2 PROTEIN, HUMAN; TUMOR ANTIGEN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTIBODY RESPONSE; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLADDER CANCER; CARCINOMA; CASTRATION RESISTANT PROSTATE CANCER; COLORECTAL CANCER; CONSTIPATION; DEHYDRATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPNEA; EMBOLISM; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GENOTYPE; HEAD AND NECK CANCER; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; IMMUNOGENICITY; KIDNEY CANCER; LEUKOCYTE COUNT; LIVER CANCER; LUNG EMBOLISM; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; NON SMALL CELL LUNG CANCER; OVARY CANCER; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RASH; SIDE EFFECT; SMALL CELL LUNG CANCER; STOMACH CANCER; TRIPLE NEGATIVE BREAST CANCER; UGT1A1 GENE; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; GENETICS; HALF LIFE TIME; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEOPLASMS; PHASE 1 CLINICAL TRIAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; TIME FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL ADHESION MOLECULES; FEMALE; GLUCURONOSYLTRANSFERASE; HALF-LIFE; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; TIME FACTORS;

EID: 85029872271     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30789     Document Type: Article

References (36)

1. de Goeij BE, Lambert JM. New developments for antibody-drug conjugate-based therapeutic approaches. Curr Opin Immunol. 2016;40:14-23.
2. Gravanis I, Tzogani K, van Hennik P, et al. The European Medicines Agency review of brentuximab vedotin (Adcetris) for the treatment of adult patients with relapsed or refractory CD30 + Hodgkin lymphoma or systemic anaplastic large cell lymphoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Oncologist. 2016;21:102-109.
3. Jerjian TV, Glode AE, Thompson LA, O'Bryant CL. Antibody-drug conjugates: a clinical pharmacy perspective on an emerging cancer therapy. Pharmacotherapy. 2016;36:99-116.
4. Govindan SV, Sharkey RM, Goldenberg DM. Prospects and progress of antibody-drug conjugates in solid tumor therapies. Expert Opin Biol Ther. 2016;16:883-893.
5. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res. 2002;8:641-661.
6. Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001;7:2182-2194.
7. Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Goldenberg DM. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011;17:3157-3169.
8. Govindan SV, Cardillo TM, Moon SJ, Hansen HJ, Goldenberg DM. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res. 2009;15:6052-6061.
9. Moon SJ, Govindan SV, Cardillo TM, D'Souza CA, Hansen HJ, Goldenberg DM. Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy. J Med Chem. 2008;51:6916-6926.
10. Cubas R, Li M, Chen C, Yao Q. Trop2: a possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta. 2009;1796:309-314.
11. Trerotola M, Cantanelli P, Guerra E, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene. 2013;32:222-233.
12. Stepan LP, Trueblood ES, Hale K, Babcook J, Borges L, Sutherland CL. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J Histochem Cytochem. 2011;59:701-710.
13. Starodub AN, Ocean AJ, Shah MA, et al. First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res. 2015;21:3870-3878.
14. Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015;6:22496-22512.
15. Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
16. Sharkey RM, McBride WJ, Cardillo TM, et al. Enhanced delivery of SN-38 to human tumor xenografts with an anti-Trop-2-SN-38 antibody conjugate (sacituzumab govitecan). Clin Cancer Res. 2015;21:5131-5138.
17. Innocenti F, Schilsky RL, Ramirez J, et al. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol. 2014;32:2328-2334.
18. Cardillo TM, Govindan SV, Sharkey RM, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers. Bioconjug Chem. 2015;26:919-931.
19. Garrett CR, Bekaii-Saab TS, Ryan T, et al. Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer. Cancer. 2013;119:4223-4230.
20. Kurzrock R, Goel S, Wheler J, et al. Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. Cancer. 2012;118:6144-6151.
21. Patnaik A, Papadopoulos KP, Tolcher AW, et al. Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. Cancer Chemother Pharmacol. 2013;71:1499-1506.
22. Perez EA, Awada A, O'Shaughnessy J, et al. Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2015;16:1556-1568.
23. Hoch U, Staschen CM, Johnson RK, Eldon MA. Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemother Pharmacol. 2014;74:1125-1137.
24. Pfizer Inc. Camptosar-irinotecan hydrochloride injection, solution [prescribing information, package insert]. New York: Pfizer Inc; 2016. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=533. April, 2016.
25. Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2:51-63.
26. Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol. 1996;14:709-715.
27. Saltz LB. Clinical use of irinotecan: current status and future considerations. Oncologist. 1997;2:402-409.
28. Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther. 2002;72:265-275.
29. Bardia A, Mayer IA, Diamond JR, et al. Efficacy and safety of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU 132), in heavily pretreated patients with metastatic triple-negative breast cancer [published online ahead of print March 14, 2017]. J Clin Oncol. doi: 10.1200/JCO.2016.70.8297.
30. Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J Clin Oncol. 2002;20:3293-3301.
31. van Osdol W, Fujimori K, Weinstein JN. An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a “binding site barrier.” Cancer Res. 1991;51:4776-4784.
32. Vasalou C, Helmlinger G, Gomes B. A mechanistic tumor penetration model to guide antibody drug conjugate design [serial online]. PLoS One. 2015;10:e0118977.
33. Camidge RD, Heist RS, Masters GA, et al. Therapy of metastatic, non-small cell lung cancer (mNSCLC) with the anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132) [abstract]. J Clin Oncol. 2016;34(suppl). Abstract 9011.
34. Faltas B, Goldenberg DM, Ocean AJ, et al. Sacituzumab govitecan, a novel antibody-drug conjugate, in patients with metastatic platinum-resistant urothelial carcinoma. Clin Genitourin Cancer. 2016;14:e75-E79.
35. Starodub AN, Camidge RD, Scheff RJ, et al. Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132), in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC) [abstract]. J Clin Oncol. 2016;34(suppl). Abstract 8559.
36. Cardillo TM, Sharkey RM, Rossi DL, Arrojo R, Mostafa A, Goldenberg DM. Synthetic lethality exploitation by an anti-Trop-2-SN-38 antibody-drug conjugate, IMMU-132, plus PARP-inhibitors in BRCA1/2-wild-type triple-negative breast cancer [published online ahead of print January 9, 2017]. Clin Cancer Res. doi: 10.1158/1078-0432.CCR-16-2401.